Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: Possible relation to diabetic microvascular complications

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 5, 2014, Pages 451-457

  Sherif, Eman M ^a   Elbarbary, Nancy S ^a   Aziz, Manal M Abd Al ^b   Mohamed, Samar F ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Children and adolescents; Lipid profile; Microvascular complications; Thrombin activatable fibrinolysis inhibitor; Type 1 diabetes

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN; PIG INSULIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRIACYLGLYCEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADOLESCENT DISEASE; ALBUMIN TO CREATININE RATIO; ALBUMIN URINE LEVEL; ARTICLE; BLOOD PRESSURE; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREDICTIVE VALUE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; URINE LEVEL; ADULT; BLOOD; DIABETES MELLITUS; FIBRINOLYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; FIBRINOLYSIS; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; YOUNG ADULT;

EID: 84905038877     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000080     Document Type: Article

References (39)

1. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009; 67: 376-387; Review.
2. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77-82. (Pubitemid 351556223)
3. Targher G, Chonchol M, Zoppini G, Franchini M. Hemostatic disorders in type 1 diabetes mellitus. Semin Thromb Hemost 2011; 37: 58-65.
4. Bajzar L, Manuel R, Nesheim M. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
5. Yano Y, Kitagawa N, Gabazza EC, Morioka K, Urakawa H, Tanaka T, et al. Increased plasma thrombin activatable fibrinolysis inhibitor level in normotensive type 2 diabetic patients with microalbuminurea. J Clin Endocrinol Metab 2003; 88: 736-741. (Pubitemid 36207816)
6. Meltzer ME, Lisman T, Groot PG, Meijers JC, le Cessie S, Doggen CJ, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
7. Antovic JP, Yngen M, Ostenson C, Antovic A, Wallen HN. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis 2003; 14: 551-556. (Pubitemid 37083170)
8. Harmanci A, Kandemir N, Dagdelen S, Gonc N, Buyukasik Y, Alikasifoglu A, et al. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state. J Diabetes Complic 2006; 20: 40-44. (Pubitemid 43028412)
9. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-S69.
10. Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complic 2007; 21: 13-19. (Pubitemid 46001745)
11. Wilkinson CP, Ferris 3rd FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682. (Pubitemid 37025422)
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of ultracentrifuge. Clin Chem 1972; 18: 499-502.
13. Chetaille P, Alessi MC, Chetakouassi D, Morange PE, Juhan VI. Plasma TAFI-antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-905. (Pubitemid 30411691)
14. Tabaei B, Al-Kassab A, Zawaski C, Herman W. Does microalbuminuria predict diabetic nephropathy? Diabetic Care 2001; 24: 1560-1566. (Pubitemid 33716449)
15. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetes patients. Diabetes 1993; 42: 1-7. (Pubitemid 23013788)
16. Di Mario U, Pugliese G. 15th Golgi lecture: from hyperglycemia to the dysregulation of vascular remodeling in diabetes. Diabetologia 2001; 44: 674-692. (Pubitemid 32846022)
17. Parving HH, Nielsen FS, Bang LE, Smidt UM, Svendsen TL, Chen JW, et al. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. Diabetologia 1996; 39: 1590-1597. (Pubitemid 26397372)
18. Stehouwer CDA, Gal MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction and chronic low-grade inflammation in type 2 diabetes, progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165. (Pubitemid 34438363)
19. Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, Orchard TJ, The Pittsburgh Epidemiology of Diabetes Complications Study. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. J Diabetes Complic 2005; 19: 183-193.
20. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving HH, Rossing P. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008; 31: 1170-1176.
21. Lin J, Glynn RJ, Rifai N, Lin J, Glynn RJ, Rifai N, et al. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 2008; 31: 2338-2343.
22. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort Study Group. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008; 31: 2006-2012.
23. Soedamah-Muthu SS, Chaturvedi N, Pickup JC, Fuller JH, EURODIAB Prospective Complications Study Group; The EURODIAB Prospective Complications Study (PCS). Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. Diabetologia 2008; 51: 493-501.
24. Chudý P, Kotuličová D, Staško J, Kubisz P. The relationship among TAFI, t-PA, PAI-1 and F1±2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Natl Center Hemostasis Thromb 2011; 22: 493-498.
25. Verkleij CJ, Nieuwdorp M, Gerdes VE, Mörgelin M, Meijers JC, Marx PF. The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2009; 102: 460-468.
26. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005; 28: 2211-2216. (Pubitemid 41242470)
27. Corrêa-Giannella ML, Vieira SM. Genetic susceptibility to microangiopathy development in type 1diabetes mellitus. Arq Bras Endocrinol Metabol 2008; 52: 375-386.
28. Agrawal RP, Ranka M, Beniwal R, Sharma S, Purohit VP, Kochar DK, Kothari RP. Prevalence of micro and macro complications in type 2 diabetes and their risk factors. Int J Diab Dev Countries 2004; 24: 11-16.
29. Wijesuriya MA, De-Abrew WK, Weerathunga A, Perera A, Vasantharajah L. Association of chronic complications of type 2 diabetes with the biochemical and physical estimations in subjects attending single visit screening for complications. J Diabetol 2012; 1: 3.
30. Jungmann E, Hellig T, Jungmann G, Mertens C, Snelting U. Intensified conventional insulin therapy in patients with type 2 diabetes mellitus: positive long-term effects of insulin lispro on metabolic control and microalbuminuria. Fortcshr Med Orig 2001; 118: 141-146.
31. Olsen BS, Johannesen J, Sjolie AK, Olsen BS, Johannesen J, Sjolie AK, et al. Metabolic control and prevalence of microvascular complications in young Danish patients with Type 1 diabetes mellitus. Diabet Med 2003; 16: 79-85.
32. Bulum T, Duvnjak L, Prkacin I. Lower levels of HDL2 cholesterol are associated with microalbuminuria in patients with type 1 diabetes. Act Med Croatica 2011; 65: 243-250.
33. Maahs DM, Maniatis AK, Nadeau K, Wadwa RP, McFann K, Klingensmith GJ. Total cholesterol and high-density lipoprotein levels in pediatric subjects with type 1 diabetes mellitus. J Pediatric 2005; 147: 544-546. (Pubitemid 41446553)
34. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, et al. Diabetic nephropathy in 27 805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007; 30: 2523-2528. (Pubitemid 47547787)
35. Marcovecchio M, Dalton R, Prevost A, Acerini C, Barrett T, Cooper J, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 2009; 32: 658-663.
36. Al-Naama LM, Kadhim M, Al-Aboud MS. Lipid profile in children with insulin dependent diabetes mellitus. J Pak Med Assoc 2002; 52: 29-34.
37. Ogbera AO, Fasanmade OA, Chinenye S, Akinlade A. Characterization of lipid parameters in diabetes mellitus - a Nigerian report. Int Arch Med 2009; 2: 19.
38. Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis 1989; 9: 934-939. (Pubitemid 20002226)
39. Kobayashi Y, Fukuo Y, Shibuya T, Terashi A. The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects. Nihon Ronen Igakkai Zasshi 1990; 27: 578-583. (Pubitemid 20386709)